Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma

Y. J.L. Jansen*, E. A. Rozeman, R. Mason, S. M. Goldinger, M. H. Geukes Foppen, L. Hoejberg, H. Schmidt, J. V. Van Thienen, J. B.A.G. Haanen, L. Tiainen, I. M. Svane, S. Mäkelä, T. Seremet, A. Arance, R. Dummer, L. Bastholt, M. Nyakas, O. Straume, A. M. Menzies, G. V. LongV. Atkinson, C. U. Blank, B. Neyns

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

Fingerprint

Dive into the research topics of 'Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma'. Together they form a unique fingerprint.

Medicine & Life Sciences